The U.S. Court of Appeals for the Federal Circuit upheld a Patent Trial and Appeal Board decision invalidating three patents asserted by 10x Genomics against Parse Biosciences. The ruling affirms that the challenged claims were unpatentable as obvious, further tightening patent boundaries around single-cell assays such as Evercode Whole Transcriptome. Parse had challenged the patents in a review, and 10x appealed the PTAB invalidation. The appellate decision stands, though it does not affect a separate Delaware district court ruling from last year tied to a different patent covering split-pool barcoding. For 10x and the single-cell market, the decision increases uncertainty around freedom-to-operate for specific assay components and may shift licensing or product roadmaps. For Parse, the win strengthens its position after its acquisition by Qiagen in late 2025.